Wall Street investors send shares of St. Jude Medical up yesterday and down today after the company reveals a warning letter from the FDA over its Sylmar, Calif., Durata defibrillator lead plant.

A warning letter from the FDA to St. Jude Medical (NYSE:STJ) sent the St. Paul, Minn.-based medical device company's stock on a seesaw ride yesterday and today.
STJ shares closed up 1.5% yesterday at $38.85 each after St. Jude revealed the warning letter, but closed down 1.2% today at $38.39 apiece.
The FDA clears OrthoSensor's Verasense device, designed to help surgeons fit knee replacement...
ArtVentive Medical Group wins CE Mark approval in the European Union for its EOS peripheral vascular...
The FDA hits Endologix's catheter introducer device recall with Class I status, its most serious...
A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology...
Experts fear the online health insurance marketplace will be burdened with tech problems and...